natgillin/translations-raw huggingface dataset:
A total of 11,250 patients with type 2 diabetes were treated in 10 double-blind, placebo- and active-controlled clinical studies, of which 7,015 received empagliflozin (empagliflozin 10 mg: 3021 patients; empagliflozin 25 mg: 3994 patients).
V 10 dvojno slepih, s placebom in zdravilno učinkovino nadzorovanih kliničnih študijah, je bilo zdravljenih skupaj 11.250 bolnikov s sladkorno boleznijo tipa 2, od tega jih je 7.015 prejemalo empagliflozin (empagliflozin 10 mg: 3.021 bolnikov; empagliflozin 25 mg: 3.994 bolnikov).
A total of 112 (64%) patients received subsequent crizotinib treatment.
Poznejše zdravljenje s krizotinibom je prejelo skupno 112 (64 %) bolnikov.
A total of 114 patients with previously treated chronic ITP were randomised 2:1 eltrombopag (n=76) to placebo (n=38).
Skupaj je bilo randomiziranih 114 bolnikov s predhodno zdravljeno kronično ITP v razmerju 2:1, eltrombopag (n = 76), placebo (n = 38).
A total of 116 patients were randomised to receive bevacizumab 3 mg/kg every 2 weeks (n=39), 10 mg/kg every 2 weeks; (n=37), or placebo (n=40).
Skupno so 116 bolnikov randomizirali v skupino, ki je prejemala 3 mg/kg bevacizumaba na 2 tedna (n = 39), v skupino, ki je prejamala 10 mg/kg bevacizumaba na 2 tedna (n = 37) in v skupino, ki je prejemala placebo (n = 40).
A total of 118 patients were enrolled: 57 % male, 80 % Caucasian, and 78 % genotype 1, 64 % ≤ 12 years of age.
V študijo je bilo vključenih 118 bolnikov; od tega je bilo 57 % moških, 80 % bolnikov bele rase, 78 % bolnikov z genotipom 1 in 64 % otrok, starih ≤12 let.
A total of 118 patients were enrolled: 57 % male, 80 % Caucasian, and 78 % genotype 1,64 %  12 years of age.
V študijo je bilo vključenih 118 bolnikov; od tega je bilo 57 % moških, 80 % bolnikov bele rase, 78 % bolnikov z genotipom 1 in 64 % otrok, starih  12 let.
A total of 1222 patients were treated with Brimica Genuair 340 micrograms
Zdravilo Brimica Genuair 340 mikrogramov/12 mikrogramov je skupaj prejemalo 1.222 bolnikov.
A total of 1226 patients were randomised (1:1) to receive either ZALTRAP (N=612; 4 mg/kg as a 1 hour intravenous infusion on day 1) or placebo (N=614), in combination with 5-fluouracil plus irinotecan [FOLFIRI: irinotecan 180 mg/m2 intravenous infusion over 90 minutes and folinic acid (dl racemic) 400 mg/m² intravenous infusion over 2 hours at the same time on day 1 using a Y-line, followed by 5-FU 400 mg/m² intravenous bolus, followed by 5-FU 2400 mg/m² continuous intravenous infusion over 46-hours].
Skupaj 1226 bolnikov so v razmerju 1:1 randomizirali bodisi na prejemanje zdravila ZALTRAP (n = 612, 4 mg/kg v 1-urni intravenski infuziji 1. dan) bodisi placeba (n = 614), v kombinaciji s 5-fluouracilom in irinotekanom [FOLFIRI: irinotekan 180 mg/m2 v 90-minutni intravenski infuziji ter folinska kislina (dl-racemat) 400 mg/m2 v 2-urni intravenski infuziji hkrati 1. dan po Y-liniji, nato pa 5-FU 400 mg/m2 v intravenskem bolusu, ki mu sledi 5-FU 2400 mg/m2 v stalni intravenski infuziji v teku 46 ur].
A total of 13 out of 83 subjects who participated in pivotal study developed an antibody capable of binding to recombinant human hyaluronidase (rHuPH20) at least once during the clinical study.
Pri skupno 13 od 83 preiskovancev, ki so sodelovali v ključni študiji, so se vsaj enkrat med klinično študijo pojavila protitelesa, zmožna vezave na rekombinantno humano hialuronidazo (rHuPH20).
A total of 1324 patients enrolled in OSLER.
Študija OSLER je zajela skupno 1324 bolnikov.
A total of 133 patients were randomised, of whom 129 received at least one dose of study treatment (64 in the olaratumab plus doxorubicin arm and 65 in the doxorubicin arm).
133 bolnikov, od tega jih je 129 prejelo vsaj en odmerek preiskovanega zdravljenja (64 v skupini, zdravljeni s kombinacijo olaratumaba in doksorubicina, in 65 v skupini, zdravljeni samo z doksorubinicom).
A total of 14 neutropenic patients with microbiologically confirmed invasive candidiasis (MITT population) were enrolled in the study (11 anidulafungin; 3 caspofungin).
V študijo so vključili skupno 14 nevtropeničnih bolnikov z mikrobiološko potrjeno invazivno kandidozo (populacija MITT) (11 jih je prejemalo anidulafungin, 3 pa kaspofungin).
A total of 14 surgeries were performed in 14 patients of which 13 were major surgeries and 1 was minor.
Pri 14 bolnikih je bilo opravljenih 14 kirurških posegov; 13 od teh je bilo večjih in 1 manjši.
A total of 14.3% of patients receiving apremilast had observed weight loss between 5-10% while 5.7% of the patients receiving apremilast had observed weight loss greater than 10%.
Skupno je 14,3 % bolnikov, ki so prejemali apremilast, opazilo zmanjšanje telesne mase med 5 in 10 %, medtem ko je 5,7 % bolnikov, ki so prejemali apremilast, opazilo izgubo telesne mase, večjo od 10 %.
A total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic children aged 6-12 years old) participated in clinical studies of oseltamivir given for the treatment of influenza.
Skupno 1473 otrok (vključujoč drugače zdrave otroke, stare 1–12 let, in otroke z astmo stare 6–12 let) je sodelovalo v kliničnih študijah, kjer je bil oseltamivir dan za zdravljenje gripe.
A total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic children aged 6-12 years old) participated in clinical studies of oseltamivir given for the treatment of influenza.
Skupno 1473 otrok (vključujoč drugače zdrave otroke, stare 1–12 let, in otroke z astmo, stare 6–12 let) je sodelovalo v kliničnih študijah, kjer je bil oseltamivir dan za zdravljenje gripe.
A total of 15 paediatric patients (aged 2 months to 12 years) received Soliris in aHUS Study C09- 001r.
V študiji aHUS C09-001r je bilo skupaj zdravljenih 15 pediatričnih bolnikov (starih od 2 meseca do 12 let) z zdravilom Soliris.
A total of 15,776 individuals (10,495 subjects 16 through 26 years of age and 5,281 adolescents 9 through 15 years of age at enrolment) received Gardasil 9.
Cepivo Gardasil 9 je skupno prejelo 15.776 oseb (10.495 oseb, ki so bile ob vključitvi stare od 16 do 26 let, in 5.281 mladostnikov, ki so bili ob vključitvi stari od 9 do 15 let).
A total of 1528 patients were randomised in equal proportions to the following two arms:
Skupno je bilo randomiziranih 1528 bolnic v enakih razmerjih v naslednji dve skupini:
A total of 154 patients (methylnaltrexone bromide 0.15 mg/kg, n = 47; methylnaltrexone bromide 0.3 mg/kg, n = 55, placebo, n = 52) were treated in the double-blind period.
Vključenih in zdravljenih v dvojno slepem obdobju je bilo skupaj 154 bolnikov (metilnaltreksonijev bromid 0,15 mg/kg, n = 47, metilnaltreksonijev bromid 0,3 mg/kg, n = 55, placebo, n = 52).
A total of 16 patients (4.4%) were  75 years old.
Skupaj je bilo 16 bolnic (4,4 %) starejših od 75 let.
A total of 169 patients (47.1 %) completed ≥ 6 cycles maintenance treatment with pemetrexed, representing at least 10 total cycles of pemetrexed.
Skupno je 169 bolnikov (47,1 %) zaključilo ≥ 6 ciklov vzdrževalnega zdravljenja s pemetreksedom , kar predstavlja vsaj 10 polnih ciklov pemetrekseda.
A total of 1717 asymptomatic or mildly symptomatic chemotherapy-naive patients were randomized 1:1 to receive either enzalutamide orally at a dose of 160 mg once daily (N = 872) or placebo orally once daily (N = 845).
Skupaj 1717 asimptomatskih ali blago simptomatskih bolnikov, ki se predhodno še niso zdravili s kemoterapijo, so v razmerju 1:1 randomizirali v skupino, ki je prejemala enzalutamid peroralno v odmerku 160 mg enkrat na dan (N = 872) ali placebo peroralno enkrat na dan (N = 845).
A total of 173 patients subsequently enrolled in an extension trial in which patients received 2 mg/kg of elosulfase alfa every week or 2 mg/kg every other week, and then all were switched to 2 mg/kg every week upon availability of the Week 24 results.
Skupaj 173 bolnikov je bilo nato vključenih v podaljšanje preskušanja, v katerem so bolniki vsak teden prejemali elosulfazo alfa v odmerku 2 mg/kg telesne mase ali vsak drugi teden v odmerku 2 mg/kg telesne mase, ko pa so bili na voljo rezultati v 24. tednu, so vsi bolniki prejemali zdravilo v odmerku 2 mg/kg telesne mase enkrat tedensko.
A total of 1774 patients received avanafil, which was taken as needed at doses of 50 mg (one study), 100 mg and 200 mg (four studies), respectively.
Avanafil je prejemalo skupno 1.774 bolnikov, ki so ga jemali v odmerkih po 50 mg (ena študija) oziroma 100 mg in 200 mg (štiri študije).
A total of 18% of patients had a history of psoriatic arthritis.
Vsega skupaj 18 % bolnikov je imelo anamnezo psoriatičnega artritisa.
A total of 1935 patients were randomised to double- blind medication and approximately 70% were also using a long-acting muscarinic antagonist (LAMA) through the course of the trial.
Na dvojno slepo zdravljenje je bilo vsega skupaj randomiziranih 1.935 bolnikov, približno 70 % bolnikov pa je med preskušanjem uporabljalo tudi dolgodelujoče antagoniste muskarinskih receptorjev (LAMA).
A total of 199 subjects 2-5 years of age were in the Menveo per protocol immunogenicity population and 81 subjects 3-5 years of age were in the ACWY-PS group.
Skupaj 199 oseb, starih 2–5 let, je bilo v skupini s cepivom Menveo po protokolu populacije imunogenosti in 81 oseb, starih 3–5 let, je bilo v skupini ACWY-PS.
A total of 2,106 patients received insulin glargine 100 units/ml in all trials combined.
Skupno je v vseh preskušanjih insulin glargin 100 enot/ml prejemalo 2 106 bolnikov.
A total of 2,192 patients were treated; for both groups, patients were treated for at least 5 days and up to 26 days (mean 7 days).
Zdravili so vsega skupaj 2.192 bolnikov; bolnike iz obeh skupin so zdravili vsaj po 5 dni in do 26 dni dolgo (povprečno po 7 dni).
A total of 2,365 patients with type 2 diabetes were treated with Eperzan and 2,530 received other study medications in 8 active and placebo-controlled phase III clinical trials.
V 8 kliničnih preskušanjih III. faze, kontroliranih z zdravilnimi učinkovinami oziroma placebom, je zdravilo Eperzan dobivalo skupaj 2.365 bolnikov s sladkorno boleznijo tipa 2, 2.530 pa jih je dobivalo druga raziskovana zdravila.
A total of 2,866 patients were randomized and 2,856 patients were treated.
Skupno so razvrstili 2866 bolnikov, zdravljenih pa jih je bilo 2856.
A total of 2,876 patients have been tested for anti-tocilizumab antibodies in the 6-month controlled clinical trials.
V šestmesečnih kontroliranih kliničnih preskušanjih so protitelesa proti tocilizumabu preverili pri skupaj 2876 bolnikih.
A total of 20 subjects (12 T/LAIV, 0.3%; 8 injectable influenza vaccine, 0.2%) were hospitalized in association with medically significant wheezing.
V celoti je bilo zaradi zdravstveno pomembnega piskajočega dihanja v bolnišnico sprejetih 20 preiskovancev (12 (0,3 %) v skupini s T/LAIV in 8 (0,2 %) v skupini s cepivom proti gripi za injiciranje).
A total of 201 Cushing’s disease patients received Signifor in phase II and III studies.
V študijah faze II in III je skupno 201 bolnik s Cushingovo boleznijo prejemal zdravilo Signifor.
A total of 211 adult and paediatric CAPS patients (including FCAS/FCU, MWS, and NOMID/CINCA) have received Ilaris in clinical trials.
Skupno je v kliničnih študijah prejemalo zdravilo Ilaris 211 odraslih in pediatričnih bolnikov s CAPS (vključno s sindromi FCAS/FCU, MWS in NOMID/CINCA).
A total of 217 subjects aged 18-65 years received IXIARO together with inactivated rabies vaccine (Rabipur) in a rapid immunisation schedule on Day 0 and Day 7 and 56 subjects received IXIARO alone in the conventional immunisation schedule on Day 0 and Day 28.
Skupno 217 oseb med 18. in 65. letom starosti je prejelo cepivo IXIARO skupaj z deaktiviranim cepivom proti steklini (Rabipur) med urnikom hitre imunizacije, in sicer na dan 0 in dan 7, 56 oseb pa je prejelo zgolj cepivo IXIARO med urnikom običajne imunizacije na dan 0 in dan 28.
A total of 2184 patients were treated; for both groups, patients were treated for at least 5 days and up to 22 days (mean 7 days).
Zdravili so vsega skupaj 2.184 bolnikov; bolnike iz obeh skupin so zdravili vsaj po 5 dni in do 22 dni dolgo (povprečno po 7 dni).
A total of 2192 patients were treated; for both groups, patients were treated for at least 5 days and up to 26 days (mean 7 days).
Zdravili so vsega skupaj 2.192 bolnikov; bolnike iz obeh skupin so zdravili vsaj po 5 dni in do 26 dni dolgo (povprečno po 7 dni).
A total of 22 paediatric and adolescents patients (aged 5 months to 17 years) received Soliris in aHUS Study C10-003.
Zdravilo Soliris v študiji aHUS C10-003 je prejelo vsega skupaj 22 pediatričnih in mladostniških bolnikov (starih od 5 mesecev do 17 let).
A total of 226 (74.8%) of the Pom + LD-Dex patients and 95 (62.1%) of the HD-Dex patients were alive as of the cutoff date (07 Sep 2012).
2012) je bilo skupno živih 226 (74,8 %) bolnikov v skupini POM + NO-deks in 95 (62,1 %) bolnikov v skupini VO-deks.
A total of 23,799 patients were randomised in the clinical program (ARISTOTLE: apixaban versus warfarin, AVERROES: apixaban versus ASA) including 11,927 randomised to apixaban.
Skupno 23.799 bolnikov je bilo randomiziranih v klinični program (ARISTOTLE: apiksaban v primerjavi z varfarinom, AVERROES: apiksaban v primerjavi z acetilsalicilno kislino), pri čemer je bilo 11.927 bolnikov randomiziranih v skupino, ki je prejemala apiksaban.
A total of 23/99 (23%) MabThera-treated patients in the trial tested positive for HACA by 18 months.
Do 18. meseca je imelo pozitiven izvid HACA skupno 23 od 99 (23 %) bolnikov, ki so bili v preskušanju zdravljeni z zdravilom MabThera.
A total of 235 patients with MPS IVA were enrolled and exposed to Vimizim in six clinical trials.
Z zdravilom Vimizim je bilo izvedenih šest kliničnih preskušanj, v katerih je sodelovalo skupno 235 bolnikov z MPS IVA.
A total of 238 postmenopausal women, were randomly assigned to one of the following treatment groups; Preotact (100 micrograms parathyroid hormone), alendronate (10 mg), or the combination of both, and followed for 12 months.
Skupno 238 žensk po menopavzi so naključno razporedili v skupine tako, da so prejemale bodisi zdravilo Preotact (100 g obščitničnega hormona) bodisi alendronat (10 mg) bodisi kombinacijo navedenega, ter jih spremljali 12 mesecev.
A total of 246 ALK-positive NSCLC patients were enrolled who were treated at a Zykadia dose of 750 mg: 163 who had received prior treatment with an ALK inhibitor and 83 who were ALK inhibitor naïve.
Skupno je 246 vključenih bolnikov z ALK-pozitivnim nedrobnoceličnim pljučnim rakom prejemalo zdravilo Zykadia v odmerku 750 mg: 163 bolnikov s predhodnim zdravljenjem z zaviralcem ALK in 83 bolnikov, ki pred tem še niso prejemali zaviralca ALK.
A total of 250 patients randomized to receive bosutinib and 252 patients randomized to receive imatinib comprised the ITT population.
Populacijo, ki so jo želeli zdraviti (ITT- intended to treat), je sestavljalo 250 bolnikov, ki so bili randomizirani na prejemanje bosutiniba, in 252 bolnikov, ki so bili randomizirani na prejemanje imatiniba.
A total of 257 patients with type 2 diabetes participated in a 24-week randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of saxagliptin (5 mg once daily) in combination with metformin plus sulphonylurea (SU) in patients with inadequate glycemic control (HbA1c ≥ 7% and ≤ 10%).
Skupno 257 bolnikov s sladkorno boleznijo tipa 2 je sodelovalo v 24-tedenski randomizirani, dvojno slepi, s placebom kontrolirani študiji za oceno učinkovitosti in varnosti saksagliptina (5 mg enkrat na dan) v kombinaciji z metforminom in sulfonilsečnino (SU - sulphonylurea) pri bolnikih z nezadostno urejeno glikemijo (HbA1c ≥ 7 % in ≤ 10 %).
A total of 257 patients with type 2 diabetes participated in a 24-week randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of saxagliptin (5 mg once daily) in combination with metformin plus sulphonylurea (SU) in patients with inadequate glycemic control (HbA1c ≥ 7% and ≤ 10%).
Skupno 257 bolnikov s sladkorno boleznijo tipa 2 je sodelovalo v 24-tedenski randomizirani, dvojno slepi, s placebom kontrolirani študiji za oceno učinkovitosti in varnosti saksagliptina (5 mg enkrat na dan) v kombinaciji z metforminom in sulfonilsečnino (SU - sulphonylurea) pri bolnikih z nezadostno urejeno glikemijo (HbA1c ≥7 % in ≤10 %).
A total of 2640 adult patients with severe sepsis who were at low risk of death (e.g. patients with APACHE II<25 or with only one sepsis-induced organ failure) were enrolled in a randomised, double- blind, placebo-controlled trial (ADDRESS).
V randomiziranemu dvojno slepemu s placebom kontroliranemu preskušanju (ADDRESS) je sodelovalo skupno 2640 odraslih bolnikov s hudo sepso z nizkim tveganjem za smrt (denimo, bolniki s številom točk po lestvici APACHE II < 25 ali s sepso povzročenim okvarjenim delovanjem samo enega organa).
A total of 27 paediatric patients with leukaemia were randomized to 40, 60 or 80 micrograms/kg/day of palifermin for 3 days pre- and post- hematopoietic stem cell transplantation (HSCT).
Skupno 27 pediatričnih bolnikov z levkemijo so randomizirali v skupine s po 40, 60 in 80 mikrogrami/kg/dan palifermina v obdobju 3 dni pred in po presaditvi hematopoetskih matičnih celic.
A total of 29 major surgical procedures were performed and assessed in 19 subjects (17 adults, 1 adolescent and 1 paediatric patient <12 years of age) in study I and an extension study.
Pri 19 osebah (17 odraslih, 1 mladostnik in 1 pediatrični bolnik < 12 let starosti) v študiji I in v podaljšku študije so opravili in ocenili skupaj 29 večjih kirurških posegov.
A total of 2928 patients enrolled in OSLER-2.
Študija OSLER-2 je zajela skupno 2928 bolnikov.
A total of 30 spontaneous cases were received describing 31 adverse events according to the pre-defined preferred terms for urinary adverse events associated with umeclidinium bromide / vilanterol (UMEC/VI).
Skupno je bilo zabeleženih 30 spontanih prijav, ki so po vnaprej opredeljenih specifičnih izrazih klasifikacije NUZ za neželene učinke na sečilih opisale 31 neželenih učinkov, povezanih s kombinacijo umeklidinijev bromid/vilanterol (UMEK/VI).
A total of 305 (36.1%) of all patients were not evaluable for MMR at 48 months (98 in the nilotinib 300 mg BID group, 88 in the nilotinib 400 mg BID group and 119 in the imatinib group) due to missing/unevaluable PCR assessments (n=18), atypical transcripts at baseline (n=8), or discontinuation prior to the 48-month time point (n=279).
Skupno 305 (36,1 %) vseh bolnikov ni bilo primernih za oceno glavnega molekularnega odziva po 48 mesecih (98 v skupini z nilotinibom 300 mg dvakrat dnevno, 88 v skupini z nilotinibom 400 mg dvakrat dnevno in 119 v skupini z imatinibom), in sicer zaradi manjkajoče ocene/neocenljivega rezultata testa PCR (n=18), atipičnega izhodiščnega prepisa (n=8) ali zaradi prekinitve sodelovanja v študiji pred zaključenim obdobjem 48 mesecev (n=279).
A total of 323 patients 65 years of age and older, including 53 patients 75 years and older, received abatacept in placebo-controlled clinical trials.
V s placebom nadzorovanih kliničnih preskušanjih je abatacept prejemalo skupaj 323 bolnikov, starih 65 let in starejših, vključno s 53 bolniki, starimi 75 let in starejšimi.
A total of 323 patients 65 years of age and older, including 53 patients 75 years and older, received intravenous abatacept in placebo-controlled clinical trials.
V s placebom nadzorovanih kliničnih preskušanjih je abatacept intravensko prejemalo skupaj 323 bolnikov, starih 65 let in starejših, vključno s 53 bolniki, starimi 75 let in starejšimi.
A total of 334 patients achieving a complete or partial remission following induction therapy were randomised in a second step to MabThera maintenance therapy (n=167) or observation (n=167).
Skupno je bilo 334 bolnikov, ki so po indukcijskem zdravljenju dosegli popolni ali delni odgovor, randomiziranih v drugi del zdravljenja, v katerem so prejemali vzdrževalno zdravljenje z zdravilom MabThera (n = 167), ali v opazovano skupino (n = 167).
A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open- label extension study.
V odprti podaljšani študiji je v oceni prenehanja uporabe in ponovnega zdravljenja sodelovalo skupno 347 stabilnih odzivnih bolnikov.
A total of 350 patients were randomized (randomization ratio 1:1).
Skupaj je bilo randomiziranih 350 bolnikov (randomizacijsko razmerje 1:1).
A total of 351 were randomised to OZURDEX, 347 to dexamethasone 350 µg and 350 patients to sham.
V skupino, ki je prejela zdravilo OZURDEX, so naključno razporedili skupno 351 bolnikov, v skupino, ki je prejela 350 µg deksametazona, 347 bolnikov, v skupino, ki je prejela placebo, pa 350 bolnikov.
A total of 366 patients underwent both a Pylobactell test and a standard biopsy test (where a sample from the stomach is analysed to see if it is infected).
Skupno 366 bolnikov je bilo testiranih tako s testom na podlagi zdravila Pylobactell kot s standardnim testom na podlagi biopsije (pri katerem se analizira vzorec iz želodca, da bi ugotovili, ali je okužen).
A total of 392/3095 (12.7%) patients with rheumatoid arthritis tested positive for HACA in clinical studies following therapy with MabThera.
Skupno je bilo 392 od 3.095 (12,7 %) bolnikov z revmatoidnim artritisom v kliničnih študijah zdravljenja z zdravilom MabThera pozitivnih na HACA.
A total of 4,204 patients were treated with Taltz in clinical development studies in plaque psoriasis.
V študijah kliničnega razvoja so z zdravilom Taltz zdravili skupno 4204 bolnike, ki so imeli psoriazo s plaki.
A total of 4,550 women (2,343 Prolia & 2,207 placebo) who missed no more than one dose of investigational product in the pivotal study described above and completed the month 36 study visit agreed to enrol in a 7-year, multinational, multicentre, open-label, single-arm extension study to evaluate the long-term safety and efficacy of Prolia.
Skupaj 4.550 žensk (2.343 prejemnic zdravila Prolia in 2.207 prejemnic placeba), ki v zgoraj opisani ključni študiji niso izpustile več kot enega odmerka raziskovanega zdravila, in so zaključile obisk študije v 36. mesecu, je privolilo v sodelovanje v nadaljevalni 7-letni multinacionalni, multicentrični, odprti študiji z enim krakom za oceno dolgoročne varnosti in učinkovitosti zdravila Prolia.
A total of 40 cases were excluded from analysis as they contained only hepatic events or non-specific abdominal pain, without a diagnosis of pancreatitis or elevated serum lipase and/or amylase.
Iz analize so izključili skupno 40 primerov, ker so zajemali samo dogodke, povezane z jetri, ali nespecifične bolečine v trebuhu brez diagnoze pankreatitisa oziroma zvišanih vrednosti lipaze in/ali amilaze v serumu.
A total of 401 patients were enrolled from which 203 were treated with Enbrel.
Sodeloval je 401 bolnik in od tega so bili 203 zdravljeni z zdravilom Enbrel.
A total of 41 patients took part in the clinical study and received at least one dose of cholic acid.
V klinični študiji je sodelovalo skupno 41 bolnikov, ki so prejeli vsaj en odmerek holne kisline.
A total of 418 patients were randomised to receive either nivolumab (n = 210) administered intravenously over 60 minutes at 3 mg/kg every 2 weeks or dacarbazine (n = 208) at 1000 mg/m2 every 3 weeks.
Skupno 418 bolnikov so randomizirali na zdravljenje z nivolumabom (n = 210) v odmerku 3 mg/kg v obliki 60-minutne intravenske infuzije vsaka 2 tedna ali na zdravljenje z dakarbazinom (n = 208) v odmerku 1.000 mg/m2 vsake 3 tedne.
A total of 423 subjects were randomised 1:1 to either combination (N = 211) or dabrafenib (N = 212).
Skupno so randomizirali 423 preiskovancev v razmerju 1:1 tako, da so prejemali bodisi kombinacijo (N = 211) ali samo dabrafenib (N = 212).
A total of 445 patients with KPS > 70 were treated with either docetaxel (T) (75 mg/m2 on day 1) in combination with cisplatin (C) (75 mg/m2 on day 1) and 5-fluorouracil (F)
Skupaj je bilo zdravljenih 445 bolnikov z oceno zmogljivosti po Karnofskem > 70; prejemali so bodisi docetaksel (T) (75 mg/m2 1. dan) v kombinaciji s cisplatinom (C) (75 mg/m2